Please login to the form below

Not currently logged in
Email:
Password:

Generex publishes Oral-Lyn study

Generex has published the results of a Oral-lyn study in the Diabetes Technology & Therapeutics journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes

Generex Biotechnology, a US developer of buccal drug delivery for metabolic diseases, has published the results of a Oral-lyn study in Diabetes Technology & Therapeutics, a peer-reviewed journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes.

Oral-lyn buccal spray uses Generex's proprietary drug delivery technology, RapidMist, which administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa.

The study, entitled 'Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes' was led by Dr Jaime Guevara-Aguirre, Dr Marco Guevara-Aguirre, Dr Jeannette Saavedra, Dr Gerald Bernstein and Dr Arlan L Rosenbloom.

The results of the study showed that regular insulin and Oral-lyn had similar glucodynamic effects in subjects with type 1 diabetes receiving a twice-daily insulin analogue as baseline therapy.

Monitoring and baseline corrections with additional snacks, subcutaneous regular insulin or Generex Oral-lyn puffs resulted in glycaemic control as assessed by individual daily glycaemic responses, while normal pre-prandial glycation decreased, but not significantly.

Dr Gerald Bernstein, Generex's vice-president of medical affairs and a co-author of the article, said: "This publication is significant in that it shows consistently and clearly that equivalent amounts of Generex Oral-lyn and injected regular insulin will yield comparable blood glucose control."

Generex launched Oral-Lyn in South America in 2005.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics